Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Stuttgart, Universität Stuttgart, Dissertation, 2020
- Keyword
-
Melanoma
Immunotherapy
- Event
-
Veröffentlichung
- (where)
-
Stuttgart
- (who)
-
Universitätsbibliothek der Universität Stuttgart
- (when)
-
2020
- Creator
- Contributor
-
Morrison, Markus
- DOI
-
10.18419/opus-10952
- URN
-
urn:nbn:de:bsz:93-opus-ds-109699
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tsur, Neta
- Morrison, Markus
- Universitätsbibliothek der Universität Stuttgart
Time of origin
- 2020
Other Objects (12)
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Immunotherapy of malignant melanoma
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
The role of biomarkers in personalized immunotherapy
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Immunotherapy of malignant melanoma
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
The role of biomarkers in personalized immunotherapy
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Immunotherapy of malignant melanoma
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
The role of biomarkers in personalized immunotherapy
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy